T. Rowe Price Associates’s Cellectis CLLS Stock Holding History

T. Rowe Price Associates’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-300,000	Closed	-$10.4M	–	2542
2015 Q1	$10.4M	Buy	+300,000	New	+$10.9M	﹤0.01%	1333

Other funds holding CLLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

T. Rowe Price Associates's CLLS Position: Q2 2015 in Review

T. Rowe Price Associates sold out of Cellectis (CLLS) in Q2 2015, closing a stake of 300,000 shares — an estimated $10.4M sold.

T. Rowe Price Associates first reported a position in CLLS in Q1 2015 and held it in 1 quarter. The position peaked at $10.4M in Q1 2015. 40 funds tracked by Wall St. Rank hold CLLS as of Q2 2015.

T. Rowe Price Associates reported no remaining Cellectis position as of Q2 2015 after selling out during the quarter.
T. Rowe Price Associates sold 300,000 Cellectis shares in Q2 2015, an estimated $10.4M.
T. Rowe Price Associates first reported a position in Cellectis in Q1 2015 and held it in 1 quarter.
T. Rowe Price Associates's Cellectis position peaked at $10.4M in Q1 2015.
40 funds tracked by Wall St. Rank held Cellectis as of Q2 2015.

Based on T. Rowe Price Associates's 13F filing for Q2 2015, filed 14 Aug 2015.